DW 166HC

Drug Profile

DW 166HC

Alternative Names: 166 holmium chitosan complex; 166 holmium poliglusam; Holmium 166 chitosan; Milican

Latest Information Update: 10 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dong Wha
  • Developer Dong Wha Pharmaceutical
  • Class Antineoplastics; Organometallic compounds; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Liver cancer
  • Discontinued Brain cancer; Rheumatoid arthritis

Most Recent Events

  • 10 Feb 2016 DW 166HC is available for licensing as of 10 Feb 2016. www.dong-wha.co.kr
  • 02 Nov 2007 Clinical trials in Brain cancer in South Korea (Intratumoural)
  • 02 Nov 2007 Discontinued - Phase-II for Rheumatoid arthritis in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top